Innoplexus’ Clinical Trial Prediction Engine predicted Aducanumab Failure
Frankfurt, Germany – On March 21st, 2019, Biogen’s stock declined sharply, showing a decrease of 29%, resulting in losses to the tune of $18Bn for investors after the company ended...
Read More